Antibody News and Research RSS Feed - Antibody News and Research

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.
New breast cancer vaccine provides evidence of immunotherapy in preventing disease recurrence

New breast cancer vaccine provides evidence of immunotherapy in preventing disease recurrence

A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it is combined with a powerful immunotherapy drug. [More]
Synthetic platelet-like particles could augment natural blood clotting for treatment of traumatic injuries

Synthetic platelet-like particles could augment natural blood clotting for treatment of traumatic injuries

A new class of synthetic platelet-like particles could augment natural blood clotting for the emergency treatment of traumatic injuries - and potentially offer doctors a new option for curbing surgical bleeding and addressing certain blood clotting disorders without the need for transfusions of natural platelets. [More]
Keytruda drug gets FDA approval for treatment of advanced melanoma

Keytruda drug gets FDA approval for treatment of advanced melanoma

The U.S. Food and Drug Administration today approved a new immunotherapy drug to treat advanced melanoma, signaling a paradigm shift in the way the deadly skin cancer is treated. [More]
New antibody in HIV-infected person binds to virus

New antibody in HIV-infected person binds to virus

An NIH-led team of scientists has discovered a new vulnerability in the armor of HIV that a vaccine, other preventive regimen or treatment could exploit. [More]
Ludwig, CRI collaborate with VentiRx to conduct clinical trial with motolimod and immunotherapy agents

Ludwig, CRI collaborate with VentiRx to conduct clinical trial with motolimod and immunotherapy agents

The nonprofits Ludwig Cancer Research (Ludwig) and the Cancer Research Institute (CRI) announced today an agreement with VentiRx Pharmaceuticals Inc., a clinical stage biopharmaceutical company, to conduct a clinical trial with motolimod (VTX-2337) combined with other immunotherapy agents available to Ludwig and CRI through other industry partnerships. [More]
New way to reduce abnormal blood vessel growth and leakage in eye

New way to reduce abnormal blood vessel growth and leakage in eye

Working with mice, a multicenter team of researchers has found a new way to reduce the abnormal blood vessel growth and leakage in the eye that accompany some eye diseases. The finding could lead to the development of new drugs for wet macular degeneration and diabetic macular edema. [More]
Clinical trial to assess safety and efficacy of novel monoclonal antibody for CLL patients

Clinical trial to assess safety and efficacy of novel monoclonal antibody for CLL patients

Researchers at the University of California, San Diego School of Medicine, in partnership with the California Institute for Regenerative Medicine (CIRM) and Celgene Corporation, a New Jersey-based biopharmaceutical company, have launched a phase 1 human clinical trial to assess the safety and efficacy of a novel monoclonal antibody for patients with chronic lymphocytic leukemia (CLL). [More]
Clinical studies to treat unmet medical need post-transplantation

Clinical studies to treat unmet medical need post-transplantation

A class of biotechnology drugs called monoclonal antibodies is now being tested in clinical studies to treat an unmet medical need post-transplantation, called delayed graft function [More]
Researchers create new drug to reduce inflammation of donor organ after transplantation

Researchers create new drug to reduce inflammation of donor organ after transplantation

To reduce the number of discards and thus make more kidneys available, researchers and medical scientists from the European consortium MABSOT have created a new drug called OPN-305 to reduce inflammation of the donor organ after transplantation. [More]
XBiotech reports interim results from Phase III study for anti-cancer agent Xilonix

XBiotech reports interim results from Phase III study for anti-cancer agent Xilonix

XBiotech announced today interim results from its fast-tracked Phase III study being conducted in the US for its anti-cancer agent Xilonix. [More]
BioLegend acquires shares of Covance Antibody Services

BioLegend acquires shares of Covance Antibody Services

BioLegend, Inc. (BioLegend) acquired the shares of Covance Antibody Services Inc., a business unit of Covance, located in Dedham, Massachusetts, on August 29, 2014. [More]
Soligenix announces promising preliminary results from study on ricin toxin vaccine

Soligenix announces promising preliminary results from study on ricin toxin vaccine

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today promising preliminary results from a preclinical study with its ricin toxin vaccine RiVax™, in a non-human primate (NHP) lethal aerosol exposure model. [More]
Research report on global market for drug discovery technologies

Research report on global market for drug discovery technologies

Reportlinker.com announces that a new market research report is available in its catalogue: Drug Discovery Technologies - A Global Market Overview [More]
Blend of three monoclonal antibodies can protect monkeys against Ebola virus, says UTMB researcher

Blend of three monoclonal antibodies can protect monkeys against Ebola virus, says UTMB researcher

A leading U.S. Ebola researcher from the University of Texas Medical Branch at Galveston has gone on record stating that a blend of three monoclonal antibodies can completely protect monkeys against a lethal dose of Ebola virus up to 5 days after infection, at a time when the disease is severe. [More]
Gene therapy may offer significant advantages in prevention of botulism exposure

Gene therapy may offer significant advantages in prevention of botulism exposure

The current method to treat acute toxin poisoning is to inject antibodies, commonly produced in animals, to neutralize the toxin. But this method has challenges ranging from safety to difficulties in developing, producing and maintaining the anti-serums in large quantities. [More]
Researchers find method to expand blood stem cells used to treat cancer patients

Researchers find method to expand blood stem cells used to treat cancer patients

A team of scientists from the University of Colorado School of Medicine has reported the breakthrough discovery of a process to expand production of stem cells used to treat cancer patients. [More]
Researchers receive encouraging results from two historic pediatric HIV vaccine trials

Researchers receive encouraging results from two historic pediatric HIV vaccine trials

Applying the benefit of hindsight, researchers at Duke Medicine have reanalyzed the findings of two historic pediatric HIV vaccine trials with encouraging results. The vaccines had in fact triggered an antibody response -- now known to be associated with protection in adults -- that was previously unrecognized in the infants studied in the 1990s. [More]
Researchers develop potential antibody therapy for Sudan ebolavirus

Researchers develop potential antibody therapy for Sudan ebolavirus

Researchers from Albert Einstein College of Medicine of Yeshiva University and other institutions have developed a potential antibody therapy for Sudan ebolavirus (SUDV), one of the two most lethal strains of Ebola. [More]

Yale University researchers identify bacterial culprits that drive IBD

Yale University researchers have identified a handful of bacterial culprits that may drive inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis, using patients' own intestinal immune responses as a guide. [More]
Amgen seeks FDA approval for evolocumab to treat patients with high cholesterol

Amgen seeks FDA approval for evolocumab to treat patients with high cholesterol

Amgen today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for evolocumab seeking approval for the treatment of high cholesterol. [More]